Processa Pharmaceuticals, Inc. (PCSA) Key Metrics
PCSA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.7M
- Enterprise value
- −$257,456
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.20
PCSA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPCSA returns How much profit the business earns on the capital it uses.
PCSA financial health Debt, liquidity and how easily interest is covered.
PCSA efficiency & capital use Working capital cycle and where the cash goes.
PCSA valuation history
PCSA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PCSA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PCSA cash returned to shareholders
PCSA price vs earnings per share
PCSA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.8M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$1.8M | — | — | — | — | — | — | — | — | — |
| Price / book | 0.7 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −359.7% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −301.9% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.3% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.88 | $22.10 | $167.50 | $550.00 | $2,450.00 | $3,297.50 | $9,000.00 | $12,600.00 | $15,400.00 | $6,125.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$10.36 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$8.70 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$8.70 | — | — | — | — | — | — | — | — | — |
| Cash per share | $4.23 | — | — | — | — | — | — | — | — | — |
| Book value per share | $4.26 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $3.39 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.3M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −373.0% | −354.5% | −178.5% | −166.4% | −47.2% | −123.0% | −37.9% | −74.7% | — | — |
| Return on invested capital (ROIC) | — | — | — | −311.9% | −113.3% | −147.6% | −37.6% | −87.6% | — | — |
| Return on assets (ROA) | −245.7% | −262.9% | −154.4% | −156.3% | −44.2% | −105.5% | −27.9% | −46.5% | −120.3% | — |
| Return on tangible assets | −203.4% | −367.0% | −192.2% | −318.2% | −62.1% | −116.3% | −270.6% | −135.6% | −62.2% | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | −769.9% |
| Financial health | ||||||||||
| Total debt | — | $73,507 | $150,554 | $229,450 | $78,463 | $328,122 | $1.0M | $230,000 | $2.4M | $1.4M |
| Cash & short-term investments | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M | $15.4M | $691,536 | $1.7M | $2.8M | $2,090 |
| Net debt | −$5.5M | −$1.1M | −$4.6M | −$6.3M | −$16.4M | −$15.1M | $336,349 | −$1.5M | −$398,859 | $1.4M |
| Debt / equity | — | 0.04 | 0.03 | 0.03 | 0.00 | 0.01 | 0.13 | 0.02 | 6.56 | — |
| Debt / assets | — | 0.02 | 0.03 | 0.03 | 0.00 | 0.01 | 0.09 | 0.02 | 0.82 | 13.10 |
| Current ratio | 2.54 | 1.22 | 7.71 | 8.40 | 18.87 | 13.27 | 0.85 | 3.13 | 1.14 | 0.05 |
| Quick ratio | 2.54 | 1.22 | 7.71 | 8.40 | 18.87 | 13.27 | 0.85 | 3.13 | 1.14 | 0.05 |
| Interest coverage | — | — | — | -200.2 | — | -53.8 | -107.4 | -28.1 | -50.5 | 11.4 |
| Working capital | $3.4M | $340,988 | $4.9M | $7.4M | $17.4M | $15.0M | −$184,423 | $1.4M | $351,771 | −$2.0M |
| Invested capital | $40,359 | $578,353 | $433,516 | $1.2M | $9.1M | $7.9M | $8.3M | $8.2M | −$25,695 | −$614,503 |
| Tangible asset value | $4.4M | $1.7M | $5.0M | $7.5M | $17.4M | $14.1M | −$1.6M | −$736,764 | $373,164 | −$2.0M |
| Net current asset value | $3.4M | $340,501 | $4.8M | $7.2M | $17.3M | $13.9M | −$1.9M | −$1.5M | $341,808 | −$2.0M |
| Graham net-net per share | $2.52 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $767,247 | — | $0 | $0 | $0 |
| Share buybacks (net) | $10,404 | $15,902 | $0 | $388,843 | $64,396 | $95,212 | — | $0 | $0 | $0 |
| Capex / revenue | — | — | — | — | — | — | — | — | 412.4% | 1.2% |
| Capex / depreciation | 0.00 | 4.15 | 12.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 11.06 | 0.01 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | — | 133.8% | 85.5% |
| R&D / revenue | — | — | — | — | — | — | — | — | 18,522.3% | 25.8% |
| SG&A / revenue | — | — | — | — | — | — | — | — | 17,526.3% | 833.6% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | 4,577.8 | — |
| Days payables outstanding | 293,709.2 | 278,300.1 | 525,439.7 | 114.1 | 112.5 | 82.0 | 76.4 | 99.3 | 27,743.0 | 246.7 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | -23,165.3 | — |
| Receivables turnover | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.08 | — |
| Payables turnover | 0.00 | 0.00 | 0.00 | 3.20 | 3.24 | 4.45 | 4.77 | 3.68 | 0.01 | 1.48 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 |
| Average receivables | — | — | — | — | $151,014 | $231,754 | — | $42,146 | $62,709 | — |
| Average payables | $968,838 | $596,248 | $319,582 | $273,226 | $269,800 | $198,153 | $183,857 | $171,394 | $104,968 | $85,068 |
| Average inventory | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Intangibles / total assets | 14.7% | 0.0% | 0.0% | 0.0% | 30.4% | 35.1% | 88.6% | 79.0% | 0.0% | 0.0% |
Computed from PCSA's annual financial statements (latest annual report filed March 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PCSA valuation and financial ratios
Processa Pharmaceuticals earned a return on equity of −373.0% in fiscal 2025. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the PCSA income statement, the PCSA chart for price history, or the PCSA stock overview for the latest quote and news.
PCSA key metrics FAQ
What is Processa Pharmaceuticals's return on equity?
Processa Pharmaceuticals's return on equity (ROE) was −373.0% in fiscal 2025: net income of -$13.6 million on average shareholders' equity of $3.6 million.
Does Processa Pharmaceuticals buy back its shares?
Yes. Processa Pharmaceuticals spent $0.0 million on net share repurchases in fiscal 2025.
What is Processa Pharmaceuticals's free cash flow yield?
Processa Pharmaceuticals generated -$11.4 million of free cash flow in fiscal 2025, a free cash flow yield of −301.9% on its market value at year-end ($3.8 million).
What is Processa Pharmaceuticals's current ratio?
Processa Pharmaceuticals's current ratio was 2.54 at the end of fiscal 2025: current assets were 2.54 times current liabilities.